Non-Opioid Pain Drug Development Summit 2018

Memo

With the US in the midst of an opioid crisis, it has never been more critical for the pharmaceutical, biotechnology and academic fields to unite in a common goal to innovate and accelerate the discovery and development of novel non-opioid therapies to treat pain.



This summit and its expert speaker faculty will update you on the latest and novel RandD efforts currently ongoing in discovery and optimization of non-opioid analgesic targets and their mechanism of action. In addition, the inaugural Non-Opioid Pain Drug Development Summit will be your dedicated platform to overcome translational challenges such as animal model predictive value, biomarker identification, and proving efficacy against placebo effect.



http://www.non-opioiddrugdevelopment.com/



September 27-28, 2018



Contact:

This email address is being protected from spambots. You need JavaScript enabled to view it.

+ 1 617 455 4188



URLs:

Brochure https://go.evvnt.com/234426-0?pid=5569

Tickets https://go.evvnt.com/234426-1?pid=5569



Prices:

Conference + 1 Workshop Earlybird (Book by 15/06/18): USD 1798.0

Conference + 1 Workshop (standard rate): USD 2498.0

Conference Earlybird (Book by 15/06/18): USD 1299.0

Conference (Standard rate): USD 1999.0

Workshop: USD 499.0



Speakers: Mary Ann Pellymounter (NIH/NINDS/Division of Translational Research), Daniel Klamer (Anavex Life Sciences Corp.), Kerrie Brady (Centrexion Corp), Crist Frangaki (Achelios Therapeutics), Lucio Rovati (Rottapharm Biotech), Silviu Itescu (Mesoblast Ltd.)



Time: 8:00 am - 4:00 pm.Category: Conferences | Science, Health and Medicine



Venue details: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, 02114, United States